cepia

Clinical Epidemiology and Ageing

Reduced Sufentanil Doses are Effective for Postoperative Analgesia After Ductal Closure in Extremely Premature Infants: A 10 Years Retrospective Cohort Study.

Soreze Y, Audureau E, Decobert F, Jaby O, Blary S, Danan C, Durrmeyer X Clin J Pain. 2017;33(12):1109-1116.

<p><b>OBJECTIVES: </b>The objective of the study was to assess the efficacy of reduced sufentanil doses for postoperative analgesia following surgical ductal closure in extremely premature infants.</p><p><b>METHODS: </b>This was a retrospective, single-center, cohort study comparing 2 sufentanil dosing regimens used between 2001 and 2010 and included all infants born at <28 weeks of gestation with surgical ductal closure. Sufentanil doses were reduced in 2007 as a standard of care. Time was divided into 3 epochs to distinguish the effects of practice changes over time from the effects of sufentanil dose change: epoch 1 (2001 to 2004), epoch 2 (May 2005 to 2007), and epoch 3 (June 2007 to 2010).</p><p><b>RESULTS: </b>A total of 109 of 114 eligible infants were analyzed (mean [±SD], gestational age: 25.1 [±1.1] wk; mean [±SD], birth weight: 756 [±144] g). Median sufentanil doses were significantly higher during epochs 1 and 2 (0.1 to 0.2 µg/kg/h) than during epoch 3 (0.03 to 0.04 µg/kg/h) (P<0.0001). EDIN (Echelle de Douleur et d'Inconfort du Nouveau-né) pain scores were mostly ≤4 throughout the study period and their changes over time were not contemporaneous with the reduction in sufentanil doses; they were lower during epoch 1 versus epochs 2 and 3 (P<0.0001) and comparable between epochs 2 and 3. Midazolam doses and paracetamol use were not higher during epoch 3 as compared with epochs 1 and 2. No difference in opioid-related adverse events was observed between the 3 epochs.</p><p><b>CONCLUSION: </b>Our study supports the use of low continuous intravenous sufentanil doses, consistent with morphine doses currently recommended in this population.</p>

MeSH terms: Administration, Intravenous; Analgesics, Opioid; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Female; Humans; Infant, Extremely Premature; Infant, Newborn; Ligation; Male; Pain Measurement; Pain, Postoperative; Retrospective Studies; Sufentanil; Time Factors; Treatment Outcome
DOI: 10.1097/AJP.0000000000000487

Ajouter un commentaire

2 + 1 =